AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer. In a phase 1 trial in patients with ...

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...

Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), continues to support genitourinary cancer research with the ...